Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
Oculis Holding AG (Nasdaq: OCS) and EURETINA have announced the 2025 Ramin Tadayoni Award, continuing their collaboration to honor the legacy of Professor Tadayoni, who passed away on April 19, 2024. The award, worth €30,000 for research support plus €5,000 for the candidate, aims to support exceptional postgraduate scholars in retina research.
Applications will be accepted until May 12, 2025, with the winner to be announced at the EURETINA Congress in Paris (September 4-7, 2025). Dr. Andrea Govetto was named the inaugural recipient in 2024 for his work on developing a computational model of fluid flow and retinal tissue deformation in macular edema.
Professor Tadayoni served as Oculis' Chief Scientific Officer and was a distinguished figure in ophthalmology, having authored over 320 medical articles and received numerous prestigious awards including the Jules Gonin Award.
Oculis Holding AG (Nasdaq: OCS) e EURETINA hanno annunciato il Premio Ramin Tadayoni 2025, proseguendo la loro collaborazione per onorare l'eredità del Professor Tadayoni, scomparso il 19 aprile 2024. Il premio, del valore di €30.000 per il supporto alla ricerca più €5.000 destinati al candidato, è volto a sostenere studiosi post-laurea eccezionali nel campo della ricerca sulla retina.
Le candidature saranno accettate fino al 12 maggio 2025, con l'annuncio del vincitore previsto al Congresso EURETINA di Parigi (4-7 settembre 2025). Il dottor Andrea Govetto è stato il primo destinatario nel 2024 per il suo lavoro nello sviluppo di un modello computazionale del flusso dei fluidi e della deformazione del tessuto retinico nell'edema maculare.
Il Professor Tadayoni è stato Chief Scientific Officer di Oculis ed è stato una figura di spicco nell'oftalmologia, autore di oltre 320 articoli medici e vincitore di numerosi premi prestigiosi, tra cui il Jules Gonin Award.
Oculis Holding AG (Nasdaq: OCS) y EURETINA han anunciado el Premio Ramin Tadayoni 2025, continuando su colaboración para honrar el legado del Profesor Tadayoni, quien falleció el 19 de abril de 2024. El premio, con un valor de €30,000 para apoyo a la investigación más €5,000 para el candidato, tiene como objetivo apoyar a investigadores de posgrado excepcionales en el campo de la retina.
Las solicitudes se aceptarán hasta el 12 de mayo de 2025, y el ganador será anunciado en el Congreso de EURETINA en París (4-7 de septiembre de 2025). El Dr. Andrea Govetto fue el primer galardonado en 2024 por su trabajo en el desarrollo de un modelo computacional del flujo de fluidos y la deformación del tejido retiniano en el edema macular.
El Profesor Tadayoni fue Director Científico de Oculis y una figura destacada en oftalmología, autor de más de 320 artículos médicos y receptor de numerosos premios prestigiosos, incluido el Premio Jules Gonin.
Oculis Holding AG (나스닥: OCS)와 EURETINA는 2025년 라민 타다요니 상을 발표하며, 2024년 4월 19일에 별세한 타다요니 교수의 유산을 기리기 위한 협력을 이어가고 있습니다. 이 상은 연구 지원금 3만 유로와 후보자에게 5천 유로를 수여하며, 망막 연구 분야의 뛰어난 대학원생을 지원하는 것을 목표로 합니다.
신청 마감은 2025년 5월 12일까지이며, 수상자는 2025년 9월 4일부터 7일까지 파리에서 열리는 EURETINA 학회에서 발표됩니다. 2024년 초대 수상자는 황반부 부종에서 체액 흐름과 망막 조직 변형에 관한 계산 모델을 개발한 안드레아 고베토 박사입니다.
타다요니 교수는 Oculis의 최고 과학 책임자였으며, 320편 이상의 의학 논문을 저술하고 Jules Gonin 상을 포함한 다수의 권위 있는 상을 받은 안과학 분야의 저명한 인물입니다.
Oculis Holding AG (Nasdaq : OCS) et EURETINA ont annoncé le Prix Ramin Tadayoni 2025, poursuivant leur collaboration pour honorer l’héritage du professeur Tadayoni, décédé le 19 avril 2024. Ce prix, d’un montant de 30 000 € pour soutenir la recherche, plus 5 000 € pour le candidat, vise à soutenir des chercheurs postdoctoraux exceptionnels dans le domaine de la recherche sur la rétine.
Les candidatures seront acceptées jusqu’au 12 mai 2025, le lauréat étant annoncé lors du Congrès EURETINA à Paris (du 4 au 7 septembre 2025). Le Dr Andrea Govetto a été le premier récipiendaire en 2024 pour son travail sur le développement d’un modèle informatique du flux de fluides et de la déformation des tissus rétiniens dans l’œdème maculaire.
Le professeur Tadayoni a été directeur scientifique chez Oculis et une figure éminente en ophtalmologie, auteur de plus de 320 articles médicaux et récipiendaire de nombreux prix prestigieux, dont le Jules Gonin Award.
Oculis Holding AG (Nasdaq: OCS) und EURETINA haben den Ramin Tadayoni Award 2025 angekündigt und setzen damit ihre Zusammenarbeit fort, um das Vermächtnis von Professor Tadayoni zu ehren, der am 19. April 2024 verstorben ist. Der Preis, bestehend aus 30.000 € für die Forschungsförderung sowie 5.000 € für den Kandidaten, soll herausragende Postgraduierten im Bereich der Netzhautforschung unterstützen.
Bewerbungen werden bis zum 12. Mai 2025 entgegengenommen, der Gewinner wird auf dem EURETINA-Kongress in Paris (4.-7. September 2025) bekannt gegeben. Dr. Andrea Govetto wurde 2024 als erster Preisträger für seine Arbeit zur Entwicklung eines computergestützten Modells des Flüssigkeitsflusses und der Gewebeverformung der Netzhaut bei Makulaödem ausgezeichnet.
Professor Tadayoni war Chief Scientific Officer von Oculis und eine herausragende Persönlichkeit in der Ophthalmologie. Er verfasste über 320 medizinische Artikel und erhielt zahlreiche renommierte Auszeichnungen, darunter den Jules Gonin Award.
- None.
- None.
ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announces, in collaboration with EURETINA, the 2025 Ramin Tadayoni Award.
The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute to Professor Tadayoni, the Company’s Chief Scientific Officer and a world-renowned retina specialist, who unexpectedly passed away on April 19 2024. This award aims to encourage innovative research with the potential to significantly advance the understanding and treatment of retinal diseases.
This annual award of
Riad Sherif, M.D., Chief Executive Officer of Oculis, said: “On April 19, we mark the one-year anniversary of Prof. Tadayoni's passing, and we are deeply honored to announce our continued support for this award, commemorating the extraordinary legacy of a dear friend, leading scientist and deeply valued member of the global retina community and Oculis team. Prof. Tadayoni’s impact on the field of ophthalmology and our pipeline remains profound. Through this award, we carry forward his passion for scientific excellence, education and patient-centered innovation. His dedication to advancing retinal research inspires us, and the next generation of clinicians and scientists committed to transforming the lives of patients with blinding diseases.”
Anat Loewenstein, M.D., President of EURETINA, said: “We are proud to continue the establishment of the Ramin Tadayoni Award for a second year, honoring the memory of an extraordinary individual whose legacy continues to shape the future of retinal research and care. This award stands as a tribute to Prof. Tadayoni’s remarkable contributions to ophthalmology and to his role as a mentor and deeply respected colleague. By championing excellence in retinal research and fostering the next generation of leaders in the field, we continue to uphold his vision. We are grateful to Oculis for its ongoing support in this meaningful initiative.”
In September 2024 Dr. Andrea Govetto, M.D., Ph.D., was selected as the inaugural recipient of the Ramin Tadayoni Award in 2024. Dr. Govetto, a vitreoretinal surgeon at the Oftalmico-Fatebenefratelli Hospital, ASST-Fatebenefratelli-Sacco in Milan, Italy, is developing a computational model of fluid flow and retinal tissue deformation in macular edema.
Prof. Tadayoni joined Oculis’ Scientific Advisory Board in December 2017 and then after as Chief Scientific Officer in February 2024. At the time, he served as the President of EURETINA, the European Society of Retina Specialists and the Retina Department Chairman of Rothschild Foundation Hospital, including the French Myopia Institute. Prior, he was also Chief of the Department for Lariboisière university hospitals and Saint-Louis hospital and Professor of Ophthalmology at University Paris-Cité. Prof. Tadayoni was a Principal Investigator in numerous trials and served as an advisor for companies in the ophthalmology space for over two decades, including his role as Chair of the Oculis’ Retina Scientific Advisory Board. He was a passionate physician and researcher, authoring over 320 medical and scientific articles and making numerous contributions to ophthalmology textbooks. He received numerous awards, including the American Academy of Ophthalmology Achievement Award and the prestigious Jules Gonin Award from the Retina Research Foundation. Dr. Tadayoni completed his medical degree and internship at Paris V University. His retina fellowship was completed at Lariboisière University Hospital while simultaneously pursuing his Ph.D. in Science at Paris VII University and the Paris Vision Institute.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS / XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in clinical development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
FAQ
What is the value of the 2025 Ramin Tadayoni Award offered by Oculis (OCS)?
When is the application deadline for the 2025 Ramin Tadayoni Award by Oculis (OCS)?
Who won the inaugural Ramin Tadayoni Award from Oculis (OCS) in 2024?
When and where will the 2025 Ramin Tadayoni Award winner be announced by Oculis (OCS)?
